MedTrace Logo

Determinants of Oral Anticoagulants' Activity

NCT03172546 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 3

Last updated 2019-10-18

No results posted yet for this study

Summary

The primary objective of the present study is to determine the clinical, biological and genetic determinants of the anticoagulant activity in patients treated with either anti-IIa or anti Xa oral anticoagulants.

The secondary objective is to determine the clinical, biological or genetic determinants of hemorrhagic or thrombotic complications during a one year follow-up.

Results will lead to a better prediction of both drug response and risk of complications.

Conditions

  • Anticoagulant

Interventions

GENETIC

PK-PD genetic polymorphisms

PK-PD genetic polymorphisms analysis in patients receiving either anti-IIa or anti-Xa treatment

Sponsors & Collaborators

  • University Hospital, Lille

    lead OTHER

Principal Investigators

  • Dominique Deplanque, MD, PhD · University Hospital, Lille

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-06
Primary Completion
2019-10-15
Completion
2019-10-15

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03172546 on ClinicalTrials.gov